Rapido Revs Up for $100 Million Fundraise, Eyes $900 Million Valuation Amid Expansion Drive
- Latest News
- April 5, 2024

New Delhi [India], February 23: Gurgaon’s real estate market has always been known for setting trends, be it luxury residences, golf-course living, or mixed-use developments. Today, we are witnessing the rise of another important segment: Senior Living and Wellness Homes. Globally, senior living and wellness housing is one of the most resilient and sought-after real
READ MOREChennai, Tamil Nadu (February 02, 2026) – Kidus Optimus, the early childhood learning wing of FIITJEE Global School, has been recognised as an Excellent Preschool at the Times Education Icons 2025-26, Chennai Schools, Pre Schools and Education Institutions Survey. This recognition brings attention to something often overlooked. The importance of the first seven years of
READ MORENew Delhi | Republic Day Parade 2026 – Incredible Design, a New Delhi–based multidisciplinary design studio, has conceptualised and delivered two landmark tableaux for the Republic Day Parade 2026, translating India’s civilisational wisdom, governance ethos, and cultural continuity into powerful national narratives. Designed for the Ministry of Ayush and the State of Madhya Pradesh, the
READ MORE
Delhi/Mumbai/Bengaluru: As the capital’s AQI again breaches the ‘Severe’ 400+ mark, a new study provides concrete data for millions seeking protection. Research from Queen Mary University of London, simulating Indian urban traffic, finds the reusable Totobobo mask reduces exposure to harmful black carbon (diesel soot) by an average of 71%—significantly outperforming other common masks. KEY
READ MORE
Mumbai (Maharashtra) [India], December 2: ImmunoAdoptive Cell Therapy (ImmunoACT), the Mumbai, India-based pioneering research and cell and gene therapy development company, announced a strategic partnership with Mango Sciences, Inc., the Boston, US, and Bengaluru, IN-based data and AI company, to expand access and affordability of ImmunoACT’s NexCAR19TM chimeric antigen receptor T-cell (CAR-T) for leukaemia and
READ MORE
By Charanjeet Singh, Associate Professor, Radiology, Anschutz Medical Center CO, USA. Prostate cancer is the second most common cancer in men worldwide. While many cases are treatable in early stages, advanced prostate cancer can be harder to manage. But there’s good news: a new kind of treatment, called PSMA therapy, is offering hope to men
READ MORE